Boehringer's Ofev Likely Needs More Data For SSc-ILD, But Might Get It Postapproval

US FDA's Arthritis Advisory Committee narrowly votes to expand label for BI's nintedanib for treatment of systemic sclerosis associated interstitial lung disease, with panelists split on whether further data on its risk/benefit profile can be gathered post-approval.